<DOC>
	<DOC>NCT01569204</DOC>
	<brief_summary>The Purpose of this trial is: - to determine complete response rate (CRR) after six cycles of chemotherapy - to determine complete remission rate (CR/CRr) as final treatment outcome after completion of treatment</brief_summary>
	<brief_title>Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Procarbazine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Histologically proven classical Hodgkin lymphoma First diagnosis, no previous treatment, age: 1860 years Stage IIB with large mediastinal mass and/or extranodal lesions, stage III or IV disease Composite lymphoma or nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) Previous malignancy Prior chemotherapy or radiation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>